4D Molecular Therapeutics Inc. (FDMT) News

4D Molecular Therapeutics Inc. (FDMT): $26.39

1.14 (+4.51%)

POWR Rating

Component Grades








Add FDMT to Watchlist
Sign Up

Industry: Biotech




#343 of 360

in industry

Filter FDMT News Items

FDMT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

FDMT News Highlights

  • For FDMT, its 30 day story count is now at 2.
  • Over the past 17 days, the trend for FDMT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • AGE, AMD and COLL are the most mentioned tickers in articles about FDMT.

Latest FDMT News From Around the Web

Below are the latest news stories about 4D MOLECULAR THERAPEUTICS INC that investors may wish to consider to help them evaluate FDMT as an investment opportunity.

4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD

Designation follows interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile in patients with wet age-related macular degeneration (wet AMD) 4D-150 is the first therapeutic candidate to receive either RMAT or Breakthrough Designation for wet AMDRMAT designation follows Priority Medicines (PRIME) designation received from the European Medicines Agency (EMA) in October 2023Receiving both RMAT and PRIME enables increased coll

Yahoo | December 21, 2023

4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference

Initial interim landmark data analysis (N=50 at 24 Weeks) to be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial, on Saturday, February 3, 2024 at 4:20 p.m. ET EMERYVILLE, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company with three novel, highly targeted next generation AAV vectors currently in the clinic, today announced that the initial interim l

Yahoo | December 4, 2023

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT, or the Company), a genetic medicines company with three novel, highly targeted next generation AAV vectors currently in human clinical studies, announced today that management will participate in a fireside chat at an upcoming investor conference in November. Members of the management team will also be available for one-on-one meetings in connection with this meeting. 6th Annual Evercore IS

Yahoo | November 15, 2023

Broker Revenue Forecasts For 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Are Surging Higher

Shareholders in 4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) may be thrilled to learn that the analysts have just...

Yahoo | November 14, 2023

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

A week ago, 4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) came out with a strong set of third-quarter numbers that...

Yahoo | November 12, 2023

4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights

Rapidly advanced 4D-150 development for wet age-related macular degeneration (wet AMD): completed enrollment of PRISM Phase 2 Dose Expansion nearly two quarters earlier than expected and enrolled first patient in Population Extension cohortInterim data update from 4D-150 PRISM Phase 2 Dose Expansion (n=50; high anti-VEGF need patients) in wet AMD expected in early 2024; update on FDA feedback on Phase 3 pivotal trial plans expected in Q1 2024Received European Medicines Agency’s Priority Medicine

Yahoo | November 9, 2023

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC

Aerosolized 4D-710 was generally well tolerated with no inflammation in any lung biopsy across Cohorts 1 and 2 (1E15 & 2E15 vg; n=7) with up to 17 months follow-upPromising, reproducible, CFTR expression significantly above normal levels across all participants and all lung tissue samples collected (n=34), substantially exceeding target profileDurable clinical activity demonstrated by improvements in quality of life by CFQ-R-RD and pulmonary function by ppFEV1 through 12 months in Cohort 1FDA fe

Yahoo | November 1, 2023

4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy

Initiated single non-human primate (NHP) safety study evaluating intravenous 4D-310 combined with rituximab/sirolimus (R/S) immunosuppressive regimenAmended INGLAXA protocol to minimize risk of atypical hemolytic uremic syndrome (aHUS) associated with intravenous (IV) AAV dosing, including addition of R/S immunosuppressive regimen4D-310 combines a novel, targeted next generation AAV vector (C102) and GLA transgene for a single low dose IV delivery to cardiomyocytesInterim clinical data from INGL

Yahoo | October 30, 2023

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | October 29, 2023

Microsoft upgraded, F5 Networks downgraded: Wall Street's top analyst calls

Microsoft upgraded, F5 Networks downgraded: Wall Street's top analyst calls

Yahoo | October 26, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!